Strategies being investigated to overcome barriers to CD8+ T cell infiltration include targeting molecules expressed by tumour cells, such as CDK4/6, CXCL13, and PD-L2 [26–28] where encouraging results are observed, and further trials have been recommended. This evidence concerns the gene CD8A and neoplasm.